Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

The Joint Corp. (JYNT): Alta Fox Capital Management’s Latest Thoughts

Alta Fox Capital Management discussed The Joint Corp. (NASDAQ:JYNT) among other stocks in its Q1 2019 Investor Letter. Track down the copy of the letter here. The fund also shared its quarterly return which was 28.10%, topping the S&P 500 that gained 13.65%. For The Joint Corp (JYNT), Alta Fox Capital Management said the following:

“The Joint Corp. (JYNT)

JYNT was the company I researched most fervently in the months leading up to the fund’s April 2018 launch. I was enamored with their business model, the turnaround under a new CEO, and the attractive unit economics. I visited the company’s headquarters in Scottsdale, met with the CEO and CFO, and was prepared to make JYNT the fund’s largest position at launch.

However, in the two weeks prior to the launch of the fund, JYNT’s share price increased ~30%, dampening my enthusiasm to build a position in size after such a large rally. However, I continued to follow the company and dug deeper into the industry and unit economics.

The sell-off at the end of 2018 hit small-caps particularly hard and JYNT fell from ~$9 to $7 per share. This selloff was despite better than expected operating performance and execution. We took advantage of what seemed like indiscriminate selling in JYNT to make it our largest position in the fund with a cost basis in the mid $7.00’s. While we had confidence in the long-term thesis, we also had conviction in a short-term catalyst (namely 2019 performance/guidance). The stock more than doubled from our cost basis in Q1. Like TPNL, we remain long JYNT given our long-term conviction in the business model, though we have somewhat trimmed the position on significant strength.”

wavebreakmedia/Shutterstock.com

wavebreakmedia/Shutterstock.com

The Joint Corp. is a company that runs a plethora of chiropractic clinics, operating through two segments – Franchise Operations and Corporate Clinics. Since the beginning of the year, its shares gained 111.88%, having a closing price on May 8th of $17.65. The company’s market cap is of $243.31 million while trading at a P/E ratio of 928.95.

At Q4’s end, a total of 6 of the hedge funds tracked by Insider Monkey held long positions in this stock, same as in the previous quarter. By comparison, 3 hedge funds held shares or bullish call options in JYNT a year ago. So, let’s see which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

Among these funds, Bandera Partners held the most valuable stake in The Joint Corp. (NASDAQ:JYNT), which was worth $10.9 million at the end of the third quarter. On the second spot was Nantahala Capital Management which amassed $9.4 million worth of shares. Moreover, Skylands Capital, Renaissance Technologies, and Marshall Wace LLP were also bullish on The Joint Corp. (NASDAQ:JYNT), allocating a large percentage of their portfolios to this stock.

JYNT

Dislcosure: None.
This article is originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading...